Literature DB >> 15895555

Embryonic stem cell models of CAG repeat disease.

Matthew T Lorincz1.   

Abstract

Nine neurodegenerative disorders are caused by CAG/polyglutamine (polyQ) repeat expansions. The underlying molecular mechanisms responsible for disease specific neurodegeneration remain elusive. In vivo and in vitro models utilizing rodent tissues, immortalized human cell lines, and human post mortem samples have provided insight into disease mechanisms. Concern that cellular and molecular processes observed in these models may not faithfully reproduce human diseases or be useful to identify compounds of therapeutic utility has driven development of new disease models. In addition to their therapeutic potential, stem cells represent a renewable source of tissue that can be directed into neurons and glia and can be used to study neurodegenerative cascades from their inception. Neuronally differentiated human stem cells containing CAG repeat expansions have the potential to accurately replicate human CAG repeat diseases and may be a faithful predictor of which compounds will be of human benefit. As a first step in development of this type of model, we developed murine embryonic stem cell models to study the mechanisms of polyQ tract induced neuronal degeneration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15895555     DOI: 10.1080/14734220510007941

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.847


  41 in total

1.  Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells.

Authors:  S H Lee; N Lumelsky; L Studer; J M Auerbach; R D McKay
Journal:  Nat Biotechnol       Date:  2000-06       Impact factor: 54.908

Review 2.  Notch and presenilins in vertebrates and invertebrates: implications for neuronal development and degeneration.

Authors:  D J Selkoe
Journal:  Curr Opin Neurobiol       Date:  2000-02       Impact factor: 6.627

Review 3.  Modelling brain diseases in mice: the challenges of design and analysis.

Authors:  Kei Watase; Huda Y Zoghbi
Journal:  Nat Rev Genet       Date:  2003-04       Impact factor: 53.242

4.  Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport.

Authors:  Györgyi Szebenyi; Gerardo A Morfini; Alyssa Babcock; Milena Gould; Kimberly Selkoe; David L Stenoien; Maureen Young; Pieter W Faber; Marcy E MacDonald; Michael J McPhaul; Scott T Brady
Journal:  Neuron       Date:  2003-09-25       Impact factor: 17.173

5.  Directed differentiation of embryonic stem cells into motor neurons.

Authors:  Hynek Wichterle; Ivo Lieberam; Jeffery A Porter; Thomas M Jessell
Journal:  Cell       Date:  2002-08-09       Impact factor: 41.582

6.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.

Authors:  M DiFiglia; E Sapp; K O Chase; S W Davies; G P Bates; J P Vonsattel; N Aronin
Journal:  Science       Date:  1997-09-26       Impact factor: 47.728

7.  Transcriptional repression by REST: recruitment of Sin3A and histone deacetylase to neuronal genes.

Authors:  Y Huang; S J Myers; R Dingledine
Journal:  Nat Neurosci       Date:  1999-10       Impact factor: 24.884

Review 8.  Lessons from animal models of Huntington's disease.

Authors:  David C Rubinsztein
Journal:  Trends Genet       Date:  2002-04       Impact factor: 11.639

9.  SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat.

Authors:  E N Burright; H B Clark; A Servadio; T Matilla; R M Feddersen; W S Yunis; L A Duvick; H Y Zoghbi; H T Orr
Journal:  Cell       Date:  1995-09-22       Impact factor: 41.582

10.  Hprt(CAG)146 mice: age of onset of behavioral abnormalities, time course of neuronal intranuclear inclusion accumulation, neurotransmitter marker alterations, mitochondrial function markers, and susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  Sara J Tallaksen-Greene; Jared M Ordway; Andrew B Crouse; Walker S Jackson; Peter J Detloff; Roger L Albin
Journal:  J Comp Neurol       Date:  2003-10-13       Impact factor: 3.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.